MLTX
Moonlake Immunotherapeutics
$19.88
+$0.86 (+4.52%)Jul 27, 2026
Key metrics
The numbers that frame MLTX today
- Market cap
- $1.46B
- P/E (TTM)
- -5.6
- EV / FCF
- -5.6
- ROIC
- -174.8%
- Div yield
- 0%
- Debt / equity
- 0.4
- 52wk Low
- $5.95
- 52wk High
- $62.75
Growth
Revenue and earnings trend for MLTX
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about MLTX
Is Moonlake Immunotherapeutics a good buy?
Hold. Moonlake Immunotherapeutics has excellent momentum, but poor quality makes the setup mixed. Growth looks poor. That could put pressure on the long-term business case. We think Moonlake Immunotherapeutics is selling at a very high price.
What is the market capitalization of MLTX?
Moonlake Immunotherapeutics's market capitalization is $1.46B.
What is the P/E ratio for MLTX stock?
Moonlake Immunotherapeutics's current P/E ratio is -5.6.
What is the 52-week high for MLTX stock?
The 52-week high for Moonlake Immunotherapeutics is $62.75. The current close of $19.88 is 68.3% below that high.
What is the 52-week low for MLTX stock?
The 52-week low for Moonlake Immunotherapeutics is $5.95. The current close of $19.88 is 234.1% above that low.
Does MLTX stock pay dividends?
Moonlake Immunotherapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for MLTX?
Moonlake Immunotherapeutics's Debt / Equity ratio is 0.4.